Pfizer (PFE) Revenue — Quarter Ended Mar 29, 2026
Revenue declined sequentially from the prior quarter but increased compared to the same period last year.
Key takeaway
Quarter ended Mar 29, 2026 · FY2026 Q1
Revenue declined sequentially from the prior quarter but increased compared to the same period last year.
Financial snapshot
Reported revenue, sequential change, year-over-year change, and trailing four-quarter revenue.
Quarter revenue
$14.5B
Revenue reported for this quarter.
Quarter-over-quarter
-17.7%
Change from the immediately preceding quarter.
Year-over-year
+5.4%
Change from the comparable year-ago quarter.
Trailing four quarters
$63.3B
Sum of the latest four reported quarters.
Quarterly revenue trend
The latest four reported quarters with year-over-year comparisons.
| Period ended | Revenue | Year-over-year change |
|---|---|---|
| Jun 29, 2025 | $14.7B | +10.3% |
| Sep 28, 2025 | $16.7B | -5.9% |
| Dec 31, 2025 | $17.6B | -1.2% |
| Mar 29, 2026 | $14.5B | +5.4% |
Revenue performance
The year-over-year increase was driven by growth in several key products, partially offset by lower contributions from COVID-19 products.
Quarterly comparison
Compared to the immediately preceding quarter, revenue decreased. On a year-over-year basis, revenue was higher.
What to watch
Monitor the trajectory of COVID-19 product revenues and the ongoing performance of newer growth products.